Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323518 · ClinicalTrials.gov registry record · Phase 2
A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
A Phase 2 study, sponsored by CuraGen Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 390
- Enrollment target
NCT00323518: Completed Phase 2 study, sponsored by CuraGen Corporation.
NCT00323518 is a Phase 2 study that has completed, run by CuraGen Corporation. The registered enrollment target is 390 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (193% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00323518, a Phase 2 study, has completed, sponsored by CuraGen Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 390 participants
- Enrollment target
Study Summary
CG53135-05 (velafermin), a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis. Oral mucositis is a commonly occurring side effect of high-dose chemotherapy in patients undergoing autologous hematopoietic stem cell transplant. The objective of this Phase II trial is to confirm the safety and efficacy of CG53135-05 (velafermin) when administered as a single dose to patients at risk for developing oral mucositis.
Interventions
- DRUG placebo
- DRUG velafermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
What the finished NCT00323518 record still lists
NCT00323518 is an interventional study that assigns participants to a tested intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (193% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00323518 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00323518 about?
NCT00323518 is a clinical study titled "A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis". CG53135-05 (velafermin), a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis. Oral mucositis is a commonly occurring side effect of high-dose chemotherapy in patients undergoing autologous hematopoietic stem cell transplant....
What is the current status of trial NCT00323518?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 390 participants. The study started on 2006-05. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00323518?
The interventions under investigation include: placebo (DRUG), velafermin (DRUG).
Who is sponsoring clinical trial NCT00323518?
This trial is sponsored by CuraGen Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00323518's enrollment target sits among peer trials
390 106th of 2000 higher than 1,893 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
- NCT05997615 · 390 participants · Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia